TheRAbase is a Rheumatoid Arthritis (RA) specialized database designed to archive and validate data generated from the commonly used and new murine and rat models, as well as human samples. It is developed in the context of the Innovative Medicines Initiative (IMI) research project Be The Cure (BTCure) which aims to promote basic understanding of disease processes and develop new therapies against RA through a combination of academic and industrial resources.
TheRAbase is designed in a model-centric way in order to best represent clinical data as well as, transcriptomic, epigenomic and proteomic signatures on the effects of current therapies in the aforementioned animal models and human samples from BTCure members. Based on the Consortium’s extensive expertise on preclinical drug evaluation of existing as well as new therapeutics, TheRAbase supports the deposition of both:
1. phenotypic (immunological profiling, histopathological analysis of inflammation and structural damage) and
2. large-scale profiling (including genomic and proteomic profiling for novel biomarker identification) data on treatment responses to existing and developing drugs.
In this sense TheRAbase, does not only serve as a repository but also allows direct comparisons of the effects of various therapeutic modalities among animal models and in comparison to human samples, towards novel drug and biomarker development.
All data are entered in TheRAbase in a standardized, hierarchically structured manner designed to allow integration and interoperability across experimental platforms and organisms for further identification and validation of targets and pathways, as well as new translational biomarkers before and after specific treatments.
About Be The Cure (BTCure)
BTCure is a pan-European research initiative involving 24 academic and 14 industrial partners. The program is funded by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Union under the Innovative Medicines Initiative (IMI) platform. The IMI is currently the largest public-private partnership in Europe in the field of biomedical research and has a total budget of approximately 38 million Euros.
The aim of this initiative is to bring together academic rheumatology research and research in pharmaceutical companies in Europe to further broaden our knowledge of disease causing factors and disease progression in Rheumatoid Arthritis (RA), thereby identifying improved or targeted therapeutic treatments. The focus of BTCure will be the development of new diagnostic methods to discover the early forms of RA as well as tools to separate the different forms of RA, where different molecular mechanisms are involved and where different therapies may be required. BTCure combines academic excellence with industrial innovation towards the development of new methods for early prediction, diagnosis and treatment of rheumatoid arthritis.